Drug Pricing: Page 6
-
Getty Images
Pharma earnings outline drug law’s looming impact on sales, development
While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.
By Christopher Newman • Nov. 9, 2022 -
Khanchit+khirisutchaluai/Shutterstock.com
Sponsored by GoodRxInflation Reduction Act: What are the healthcare implications?
The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.
Oct. 31, 2022 -
Explore the Trendline➔
Elizabeth Regan/BioPharma Dive
TrendlineDrug pricing
President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.
By BioPharma Dive staff -
Sponsored by GoodRx
Worried about provider consolidation? Learn about GoodRx engagement solutions
GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.
Oct. 10, 2022 -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentAmylyx sets ALS drug price at $158,000 per year, opening new debate on cost
The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.
By Jacob Bell • Sept. 30, 2022 -
Permission granted by Novartis
Novartis warns of sales hit after federal court turns back patent appeal
The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.
By Kristin Jensen • Sept. 21, 2022 -
Jeff J Mitchell via Getty Images
Deep DiveCan biosimilars, after years of limited impact, finally make a mark in the US?
Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.
By Jonathan Gardner • Sept. 7, 2022 -
Permission granted by Akili Inc.
Q&AAkili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment
With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.
By Elise Reuter • Aug. 29, 2022 -
Courtesy of BioMarin Pharmaceutical
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
By Jacob Bell • Aug. 25, 2022 -
Permission granted by Bluebird bio
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.
By Ned Pagliarulo • Aug. 18, 2022 -
Drew Angerer/Getty Images via Getty Images
Pharma industry braces as drug pricing bill passes Congress
The Inflation Reduction Act, signed into law by President Biden in August, was one of the most significant political defeats for the industry in years, and will reshape companies’ business plans moving forward.
By Christopher Newman • Aug. 15, 2022 -
Drew Angerer/Getty Images via Getty Images
Senate passage of drug pricing bill brings major defeat closer for pharma industry
The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.
By Christopher Newman • Aug. 8, 2022 -
Getty Images
Pharma CEOs press case against drug price negotiation as bill gains support
On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.
By Christopher Newman • Aug. 4, 2022 -
Getty Images
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
UnitedHealth to offer some drugs, including insulin, at no cost share in 2023
The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.
By Rebecca Pifer • July 15, 2022 -
Justin Sullivan via Getty Images
California to manufacture its own insulin, governor says
Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”
By Susan Kelly • July 11, 2022 -
Elizabeth Regan/BioPharma Dive
Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost
ICER, an influential nonprofit, suggested in a draft report that Amylyx’s closely watched ALS treatment would not be cost effective if priced on par with a currently available treatment.
By Ned Pagliarulo • Updated June 14, 2022 -
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
By Jonathan Gardner • May 31, 2022 -
Permission granted by Biogen
Medicare premiums to remain unchanged after Aduhelm price cut spurs review
HHS Secretary Becerra had sought to cut premiums for seniors sooner, but "legal and operational hurdles" prevented a change mid-year, the department said in a Friday statement.
By Samantha Liss • May 31, 2022 -
Elizabeth Regan/BioPharma Dive
Drug price hikes moderate as rebates rise, report finds
List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.
By Ned Pagliarulo • April 21, 2022 -
Getty Images
Hospitals mark up cancer drug prices for private insurance patients, study shows
Researchers also found U.S. spending on cancer medicines rose from about $39 billion in 2015 to nearly $68 billion in 2019 largely due to manufacturer and hospital market power.
By Hailey Mensik • April 19, 2022 -
Getty Images
UK bid to battle antibiotic resistance yields first subscription-style plan
Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.
By Jonathan Gardner • April 12, 2022 -
Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug
Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial.
By Jonathan Gardner • Updated April 7, 2022 -
Getty Images
Civica targets insulin in effort to produce cheaper drugs
The nonprofit group announced ambitious plans to begin offering insulin at prices no higher than $30 per vial by early 2024.
By Kristin Jensen • March 3, 2022 -
Win McNamee / Staff via Getty Images
Biden discusses drug prices, mental health services in annual address
The president also announced a "test-to-treat" program that would allow people to receive free antiviral pills, such as Pfizer's Paxlovid or Merck's molnupiravir, after a COVID-19 test at a pharmacy.
By Shannon Muchmore • March 2, 2022 -
Retrieved from FTC.
FTC deadlocks on vote to launch study into PBM practices
The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.
By Samantha Liss • Feb. 17, 2022
Previous
